Oral Ivacaftor (VX-770) is an investigational drug that is designed to increase the time that activated cystic fibrosis transmembrane conductance regulator (CFTR) protein channels at the cell surface remain open. It has been shown to decrease pulmonary exacerbations and other respiratory symptoms in cystic fibrosis patients It is only to be used in cystic fibrosis … Continue reading